Effect of antiviral therapy in patients with acute respiratory distress syndrome after CAP (community acquired pneumonia) and H1N1 infection on health-related quality of life (HRQoL) and cognitive performance

• Conditions: acute respiratory distress syndrome; J80; Adult respiratory distress syndrome

• Registration Number: DRKS00011913
• Lead Sponsor: Charité Universitätsmedizin Berlin Klinik für Anästhesiologie m. S. Intensivmedizin Campus Benjamin Franklin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2014-04-14
• Study Start: 2017-04-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

acute respiratory distress Syndrome (ARDS);
treatment period:
8/1/2009-09/03/2011

Exclusion Criteria

(1) no written informed consent
(2) premorbid severe mental illness

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary objective of this study is a retrospective analysis of clinical routine data concerning medication (cummulative dosage: opiate, benzodiazepnes, propofol, antopsychotics), cause of infection (H1N1, non-H1N1) duration of mechanical Ventilation (days) and length of ICU (days) and duration of Delirium (days).

Secondary Outcome Measures

Name	Time	Method
HRQoL (health related quality of life) (SF-12), PTSD (posttraumatic stress disorder) (PTSS14; PDS), cognitive performance (CANTAB; VLMT) und physical capacity (6min walking test, spirometry) are evaluated in relation to duration of delirium (days). Measurement: 11/2013-4/2014.<br>